Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target
Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neutral to Overweight and announces $20 price target.
Share
Why It Matters
A stock expert thinks 4D Molecular Therapeutics is a good buy now. Watch to see if other experts agree and if the company keeps moving forward.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.